The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model.

ABSTRACT:

Background

Children with cystic fibrosis (CF) are at higher risk of severe respiratory syncytial virus (RSV) infection, which can lead to a decline in lung function. A monoclonal antibody, palivizumab (PMB), effectively prevents RSV hospitalizations; however, the high cost of PMB, approximately C$10,000 per patient per RSV season, limits its widespread use. We assess the cost-effectiveness of PMB prophylaxis in CF children less than 2 y of age from the Canadian healthcare payer's perspective.

Methods

In 2014, a Markov cohort model of CF disease and infant RSV infections in the Canadian setting was developed based on literature data. Infants were treated with monthly PMB injections over the 5-month RSV season. Lifetime health outcomes, quality-adjusted life years (QALYs) and

SUBMITTER: McGirr AA 

PROVIDER: S-EPMC5360124 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature